Date: 2016-08-22
Type of information: Collaboration agreement
Compound: antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS)
Company: Regeneron Pharmaceuticals (USA - NY) Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) (USA)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism: monoclonal antibody. The MERS antibodies have been discovered and developed pursuant to Regeneron's antibody discovery and preclinical development agreement with Sanofi and are subject to Sanofi's opt-in rights for development and commercialization.
Disease: Middle East Respiratory Syndrome (MERS)
Details: * On August 22, 2016, Regeneron Pharmaceuticals announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS). Regeneron has previously published details on how its proprietary VelociGene® and VelocImmune® technologies enabled the rapid identification and preclinical validation of these antibody candidates. HHS will provide funding to Regeneron of up to $8.9 million to support packaging and labeling of the antibodies for human use, the preparation and submission of an Investigational New Drug application with the FDA, and a National Institutes of Health-conducted clinical trial in healthy volunteers. Currently there are no approved medicines or vaccines to treat or prevent MERS, which causes severe respiratory tract infections and is associated with high death rates. Cases of MERS have been reported in the Middle East, South Korea, Europe, the United States, Africa and other countries in Asia.
Financial terms:
Latest news:
